UCB and Biogen’s dapirolizumab pegol paves path for systemic lupus erythematosus treatment
Express Pharma
NOVEMBER 13, 2024
In PHOENYCS GO, dapirolizumab pegol achieved the primary endpoint of achieving a BILAG 2004-based Composite Lupus Assessment (BICLA) response at Week 48. They will debut as a late-breaking abstract at the upcoming American College of Rheumatology (ACR) 2024 congress, which will take place from November 14 to 19, 2024.
Let's personalize your content